AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
EZZ Life Science Experiences Significant Growth with Record-Breaking Revenue and US Expansion Advancements
February 04, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,EZZ Life Science recorded substantial revenue growth in the first half of the fiscal year, demonstrating strong financial performance.,Expansion into Chinese markets saw impressive sales increases during major global shopping events.,Strat...
Biotech Ventures Eye Expansive Growth Amid Approvals and Strategic Shifts
February 04, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Telix Pharmaceuticals (ASX:TLX) anticipates significant revenue growth following upcoming FDA approvals for innovative imaging products in 2024.,Patrys (ASX:PAB) pivots to new therapeutic opportunities with its deoxymab platform, broadenin...
Resmed's Evolving Journey in Sleep Health and Digital Care
February 04, 2025 11:00 AM AEDT| By Team Kalkine MediaResmed's Evolving Journey in Sleep Health and Digital Care
Will Wellnex Life's TGA Achievement Expand Its Global Health Reach?
February 04, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,•,Wellnex Life (ASX:WNX) secures TGA market authorisation for its liquid paracetamol plus caffeine soft gel.,• The approval strengthens a diverse portfolio of liquid soft gel formulations.,• Collaboration with major retail and global heal...
Is Paragon Care Limited (ASX:PGC) Accurately Priced in the Market?
February 03, 2025 03:27 PM AEDT| By Team Kalkine MediaHighlights:,Paragon Care (ASX:PGC) appears to be overvalued by approximately 23%.,Industry peers of PGC are currently trading at a significant discount compared to their intrinsic value.,A Discounted Cash Flow (DCF) model highlights discrepancies bet...
Is Argenica Therapeutics Managing Cash Burn Effectively?
February 03, 2025 03:26 PM AEDT| By Team Kalkine MediaHighlights:,Argenica Therapeutics (ASX:AGN) has a solid cash runway of over three years.,Cash burn increased significantly last year, rising by more than half.,Company is well-positioned to raise additional funds with minimal shareholder dilution.,In...
Has Bioxyne's Impressive Growth Signal a New Era for the Company?
February 03, 2025 03:24 PM AEDT| By Team Kalkine MediaHighlights:,Bioxyne's stock has surged significantly over the past year.,Revenue growth has been a key factor behind the strong share performance.,Despite challenges, market sentiment remains high.,Bioxyne Limited (ASX:BXN), a prominent player in the...
Tariff Pressures Forecast to Increase Costs for Fisher & Paykel (ASX:FPH) in FY26
February 03, 2025 11:15 AM AEDT| By Team Kalkine MediaHighlights,Tariffs imposed on Mexico are,anticipated,to elevate manufacturing costs in FY26.,Approximately 50% of manufacturing occurs in Mexico and 50% in New Zealand, with 43% of first-half FY25 revenues generated from the U.S.,While FY25 net profi...
Innovative GI Imaging Trial in Germany Paves the Way for Next-Generation Endomicroscopy (ASX:OIL)
February 03, 2025 11:13 AM AEDT| By Team Kalkine MediaHighlights,Pre-Clinical Initiative:,A pre-clinical study has been launched at the University Medical Centre of the Johannes Gutenberg University in Mainz to assess Gen2 real-time imaging technology on gastrointestinal (GI) tract tissue.,Collaborative...
Is the Biotech Sector on the Verge of a Major Breakthrough?
February 01, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Emyria's MDMA Trial Shows Lasting PTSD Relief,: Emyria (ASX:EMD) reports its MDMA-based therapy continues demonstrating notable improvements in PTSD symptoms, even months after treatment.,Argenica's Breakthrough in Traumatic Brain Injury...
Is Paradigm Biopharmaceuticals Making Progress with its Osteoarthritis Treatment Development?
February 01, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Paradigm Biopharmaceuticals (ASX:PAR) partners with Advanced Clinical for the PARA_OA_012 phase III osteoarthritis trial.,Advanced Clinical brings a strong track record in clinical trials, patient engagement, and regulatory strategy.,The...
Are Biotech Companies Facing Unforeseen Hurdles?
February 01, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Percheron Therapeutics (ASX:PER) discontinues its lead candidate following a DMD trial setback.,Immutep (ASX:IMM) continues multiple clinical programs amid valuation challenges.,Impedimed (ASX:IPD) and Micro-X (ASX:MX1) secure funds to sup...
Is the Health Sciences Sector Experiencing Significant Change?
February 01, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Sigma Healthcare (ASX:SIG) to combine operations with Chemist Warehouse in a major industry realignment.,Biome Australia (ASX:BIO) secures funding from the Food and Beverage Accelerator for its innovative probiotic strain research.,Cynata...
Is This Quiet Stock About to Shake Up the Market?
January 31, 2025 03:31 PM AEDT| By Team Kalkine MediaHighlights:,Alterity Therapeutics' stock surged by 260% in the past year.,Recent capital raise strengthens the company's financial position.,Investors should stay informed about possible risks linked to its outlook.,Alterity Therapeutics (ASX:ATH), a...
Prescient Therapeutics Gears Up for Transformative Year with New Leadership and Key FDA Clearance
January 31, 2025 01:38 PM AEDT| By Team Kalkine MediaHighlights:,New CEO James McDonnell,appointed,and FDA clearance received for PTX-100 Phase 2 clinical trial.,Successful IND application for PTX-100 Phase 2 trial in r/,rCTCL,, with immediate initiation.,Significant progress,in,CellPryme,and,OmniCAR,d...
Race Oncology (ASX:RAC) Advances RC220 Phase 1 Trial and Strengthens Leadership Team
January 31, 2025 12:12 PM AEDT| By Team Kalkine MediaHighlights,RC220 Phase 1 Trial Progress,:,Ethics and regulatory submissions completed, with first patient treatment,anticipated,in Q1 CY2025.,Leadership Expansion,:,Appointment of Dr Megan Baldwin as an independent non-executive director, along with...
Mesoblast (ASX:MSB) Advances Ryoncil Launch Following FDA Approval
January 31, 2025 11:12 AM AEDT| By Team Kalkine MediaHighlights:,Mesoblast (,ASX:MSB,) secures $260 million funding,for the commercial launch of,Ryoncil,in the US.,Ryoncil,gains FDA approval,, leading to a 54% surge in Mesoblast shares on December 19.,Ryoncil,targets,pediatric,complications,arising fro...
ResMed Shares Surge on Q2 Earnings Report, Revenue Jumps 10%
January 31, 2025 11:11 AM AEDT| By Team Kalkine MediaHighlights,Revenue Growth:,ResMed posted a 10% year-over-year revenue increase to,$1.3 billion,, exceeding market expectations.,Profit Surge:,Operating income jumped,52%,to,$417.2 million,, while non-GAAP net income rose,29%,to,$358.3 million,.,Posit...
How Are Paradigm Biopharmaceuticals' Strategic Initiatives Shaping Its Future?
January 31, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Paradigm Biopharmaceuticals introduces a loyalty and piggyback options offer, aimed at raising over $110 million.,Shareholders can benefit from additional shares through the company's loyalty options program.,The company prepares to launc...
What’s Driving the Surge in ASX Health Stocks?
January 31, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,The S&P/ASX 200 Health Care Index rose by 3.3% last week, outperforming the general market's 1.9% increase.,Microba’s quarterly sales surged, while Mach7 Technologies initiated a $5 million share buyback.,Aroa Biosurgery faced a setback fo...
Advertise your brand on Kalkine Media